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Introduction 
Malaria is one of the most prevalent and debilitating diseases in the world. In 2010 the World 
Health Organization (WHO) reported there were 219 million clinical cases of malaria resulting 
in 660,000 deaths, most of which occurred in Africa. (CDC, 2012c) This parasite has been 
targeted by the WHO for eradication (Tanner & Savigny, 2008) after decades of focus on 
management and treatment due to spreading strains of drug-resistant malaria. (Turschner & 
Efferth, 2009, p. 206) This new battle focuses on preventing malaria infection through 
educational programs, mosquito nets and insecticide. In addition to these efforts, research is 
being conducted into the creation of a malaria vaccine. However the development of this vaccine 
has proven enormously costly and despite a successful trial (Times, 2013) it still remains to be 
seen if the current development will be more effective than the tried and tested methods. 
 This paper will begin with a description of malaria and the unique challenges facing 
researchers as well as an examination of the impacts of malaria on Africa. It will then investigate 
the impact that the current eradication efforts have had on the disease and provide historical 
context for malaria eradication. The malaria vaccine will then be examined, both in terms of the 
successful trial of the RTS,S vaccine and the ongoing development of other vaccines. It will 
show that while the current vaccine has promise, the high cost relative to other methods of 
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infection prevention will limit the utility of the vaccine and suggest that a malaria vaccine would 
at best provide an incremental benefit to existing treatments rather than a new treatment option.  
Malaria 
 Malaria is caused by a mosquito-borne parasite of the genus Plasmodium found in 
tropical climates. Five varieties are known to exist, of which Plasmodium Falciparum is the most 
widespread and deadly. (CDC, 2012c) This is not to say that it is uniquely lethal, as P. Vivax has 
been shown to be equally dangerous (Baird, 2007, p. 533) though it is not as widespread as 
Falciparum. (Baird, 2007, p. 534) That said since Falciparum is responsible for the majority of 
deaths, it is the strain that has been the focus of vaccine research. (Sanaria, 2013) The parasite 
infects its host through mosquito saliva during feeding. It then travels to the liver to reproduce 
into its infectious form, after which it moves into the blood stream, destroying red blood cells as 
part of its reproductive process. (CDC, 2012a) If left untreated it will cause jaundice, kidney 
failure, coma and eventually death. (CDC, 2012c) 
 Developing an effective treatment or vaccine has proven difficult due to the adaptability 
of the parasite. (Turschner & Efferth, 2009, p. 206) The various species of Plasmodium show 
high genetic variance due to a rapid lifecycle and as a consequence human treatment efforts have 
created drug resistant strains. Research has also been complicated by the numerous life stages of 
the parasite, each of which requires a different method to attack. This has consequently raised the 
cost of research and spread the research focus. It has proven to be vicious cycle of increased 
research leading to increased treatment leading to the need for more research. The parasite is 
proving to be so capable of adapting to treatment that previously promising research is now 
increasingly useless. (CDC, 2010) 
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 Malaria is of particular concern not just for the substantial human cost but also for the 
economic costs. As previously mentioned, the WHO recorded 660,000 deaths in 2010, but 
estimated that the total could have been as high as 836,000 due to underreporting and 
misdiagnosis. (WHO, 2013a) Other sources indicate that the WHO estimates are still too low, 
with some claiming a million deaths per year from malaria. (Sanaria, 2013) In addition, studies 
have shown that the presence of malaria cripples economic growth and development. A study by 
the Institute for the Study of Labor indicated that the presence of malaria reduces income by half. 
Previous research had shown that countries with high incidence of malaria had a GDP per capita 
of $1,526 compared to $8,268 in non-malaria burdened countries. The study claimed that malaria 
infection accounted for approximately $3,371 of that lost productivity. (Gollin & Zimmermann, 
2007, p. 20) Prior research has shown that malaria saps the productivity and financial savings of 
nations through medical care and sick leave, ensuring that poverty remains rampant despite 
economic growth. (Sachs & Malaney, 2002, p. 684) Thus the treatment and elimination of 
malaria provides benefits not only in terms of longevity but quality of life. 
Eradication 
 Efforts to eliminate malaria from global hotspots, particularly sub-Saharan Africa, 
dropped off during the 1970’s and the focus switched to treatment. This decision came on the 
heels of successful elimination of the parasite in the United States, Caribbean and Europe. The 
change in focus has been attributed to the failure of such programs in Africa. (Tanner & Savigny, 
2008) The methods used in previous efforts simply did not appear to be as effective in Africa and 
so interest waned. In the United States, the precursor to the modern Centers for Disease Control 
and Prevention, the Office of National Defense Malaria Control Activities led the effort in what 
became known as the National Malaria Eradication Program. This program was heavily 
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dependent on the insecticide DDT, which in addition to being sprayed over breeding sites was 
applied to homes in infected areas. The agency also employed screens for doors and windows 
and the drainage of breeding sites to eliminate the disease. (CDC, 2012b) The goal was to 
prevent new infections and eliminate mosquito breeding sites. The effort proved effective. By 
1951 the disease was considered eradicated in the US and no further wild cases are reported. All 
current malarial infections of US citizens originate outside US borders. This strategy also worked 
in the Caribbean and Europe. Without a transmission vector, the parasite died out. 
 This approach was not successful in Africa, though the exact reason is uncertain. 
Elimination was being phased out while DDT was still in use so that is not the critical factor, 
though the lack of health services available is a frequently cited culprit. Regardless, modern 
eradication programs tend not to focus on the use of insecticide. Instead the programs focus on 
the use of mosquito nets and education programs to prevent bites and thus eliminate infections. 
The WHO recommends sleeping under insecticide treated nets (ITNs) as an effective means to 
prevent infection. (WHO, 2007, p. 1) Mosquitoes are opportunistic feeders and tend to be most 
active at night when victims cannot defend themselves and studies have shown that sleeping 
under a mosquito net can reduce probability of infection by 39% and using an ITN reduces rates 
by 50% for stable malaria and 43%-62% for unstable malaria. (Christian Lengeler, 2004) Thus 
the Non-Governmental Organizations (NGOs) involved in malaria eradication, of which Malaria 
No More is the most prominent, focus their efforts on providing long lasting insecticidal nets 
(LLINs) (Malaria No More, 2013) which are a newly developed form of ITN netting which is 
designed to maintain effectiveness for three years. (WHO, 2007)  
In the case of Malaria No More (MNM), the nets are provided as part of a package of 
eradication measures including providing low cost medication and dedicated education programs 
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to civilians and diagnostic equipment to health services. The intention is to convince more 
Africans to sleep under the nets that MNM provides and to change their behavior so as to not get 
infected while improving care for those who are infected. MNM contends that education is the 
critical factor in preventing infection and death and that distribution and treatment only work 
when education is also present. They may have a point. WHO statistics show that since 2006, 
when MNM began operations, malaria deaths are down by 33% in Africa. (Malaria No More, 
2013) However, one should be careful about the value of this statistic as MNM’s direct impact is 
difficult to quantify. That said Tanzania and Senegal where MNM launched its combined 
education and distribution program saw tremendous declines in infection rates, though for 
reasons not known both stopped reporting to the WHO in 2009. During their reporting period 
Senegal experienced a 67.46% decrease in reported deaths and Tanzania saw a remarkable 
95.99% decrease. Figure 1 provides the raw data on malaria deaths reported to the WHO by 
seven countries where MNM is active and three neighboring countries without an MNM 
presence (Rwanda, Ethiopia, and Sierra Leone). Figure 2 breaks the data down graphically by the 
type of aid MNM provided. 
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Figure 1 
Malaria Deaths Reported to the WHO (WHO, 2013b) 
Sierra Leone Ethiopia Rwanda Senegal Tanzania 
2006 90 1357 2486 1678 20962 
2007 324 991 1772 1935 12593 
2008 871 1169 566 741 12434 
2009 1734 1121 809 574 840 
2010 8188 1581 670 
2011 3573 936 380 
 Angola Nigeria Zambia Cameroon Chad Kenya 
 
2006 10220 6586 6484 930 837 40079 
2007 9812 10289 6183 1811 617 
2008 9465 8677 3781 7673 1018 
2009 10530 7522 3862 4943 221 
2010 8114 4328 4834 4536 886 26017 
2011 6909 3353 4540 3808 1220 713 
Sierra Leone Ethiopia Rwanda Senegal Tanzania
% decrease 2006-2009 -1826.67 17.39 67.46 65.79 95.99
Angola Nigeria Zambia Cameroon Chad
% decrease 2006-2009 -3.033 -14.21 40.44 -431.51 73.60
 
Figure 2 
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No explanation has been given by the WHO or government sources for the end of reporting by 
Senegal and Tanzania (Kenya’s gap was due to political turmoil). These two countries were the 
only beneficiaries of MNM’s combined program. Of the countries where MNM had only 
distribution or education programs only Zambia and Chad saw decreases during the period 
Senegal and Tanzania were reporting. Compared to the countries where MNM had no presence 
(Sierra Leone, Ethiopia and Rwanda) it does appear that a combined distribution and education 
program for eradication has a noticeable effect on improving survival.  
 There are no direct data on what the MNM programs cost. MNM takes pride in being the 
recipient of funds from large donors such as the Bill and Melinda Gates Foundation as well as 
private donors and does not publicly report outlays or which nets are actually being distributed. 
Since the ultimate goal of this paper is a comparison with the malaria vaccine, the focus shall be 
placed on the physical prevention measures provided, LLIN mosquito nets. These nets are 
typically given away in keeping with WHO directives and MNM goals, but still cost MNM to 
purchase. However, looking at the commercially available models of WHO approved LLINs 
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provides some indication of the cost. (WHO, 2012) Searching major online stores and 
wholesalers showed the lowest advertised retail price for bed netting was $38.99 while the 
highest retailed at $149.99. This price range will be compared to vaccine prices. The actual sales 
are likely done at wholesale prices, but the exact discount is unknown and therefore cannot be 
included. 
Malaria Vaccine 
 A vaccine against malaria has been under development for decades. This has come at 
tremendous cost and up until recently there were not any positive results. Despite positive studies 
and strong research into creating immunity to infection, no vaccine has been successfully 
brought to market. (Sanaria, 2013) There are many research and pharmaceutical companies 
involved, from multinational corporations like GlaxoSmithKline to Sanaria Inc. which only 
performs research into the malaria vaccine. Sanaria’s efforts are focused on developing a long-
lasting whole-parasite vaccine that would cause an immediate immune response to parasite 
infection, but there is no indication of when that vaccine will move from research into reality.  
GlaxoSmithKline on the other hand has a vaccine undergoing clinical trials known as 
RTS,S or mosquirix. Working on the same principle as Sanaria’s research, the RTS,S vaccine 
began an initial trial in 2011 (Kelland & Hirschler, 2011), which was completed by 2013. 
(Times, 2013) The trial was carried out in seven countries where malaria-prevention programs 
were already in effect and 75% of the participants slept under an ITN. The end result was that the 
vaccine provided immunity for 18 months in 47% of children between ages 4-17 and 27% of 
infants. (Times, 2013) The study required participants to undergo three injections of RTS,S over 
twelve months. (Kelland & Hirschler, 2011) No information is currently available about 
effectiveness after 18 months.  
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Bringing RTS,S to this stage cost GlaxoSmithKline $350 million, and it has received an 
additional $200 million from the Gates Foundation for clinical trials and final preparation. 
(Times, 2013) Sanaria has received grants totaling $35 million for the current fiscal year. 
(Sanaria, 2013) Given the high costs associated with the creation of the vaccine, 
GlaxoSmithKline has been tightlipped about the final price of the vaccine, saying only that it 
would be priced as low as possible. This is indicated to be five percent over manufacturing cost. 
(Kelland & Hirschler, 2011) While it is therefore impossible to guess the final price to 
purchasers (who will likely provide it to patients well below cost or free) it may be possible to 
extrapolate based on the cost of other GlaxoSmithKline vaccines. The CDC buys from 
GlaxoSmithKline among other companies and keeps pricing schedules for all their vaccine 
purchases. On the low end, GlaxoSmithKline sells the CDC its adult flu vaccine for $5.89 per 
dose, which is available for private sector purchase for $9.50 per dose. On the high end the HPV 
vaccine’s CDC price is $100.85 and the private cost is $128.75 per dose. (CDC, 2013) The CDC 
explains the price difference as a function of its research-grant program, allowing it to buy 
discounted drugs that it has helped fund. The private price reflects the actual cost and profit 
margin of the manufacturers. Thus it makes sense that GlaxoSmithKline would sell an 
organization like MNM the private-sector price. These price extremes will be used to evaluate 
the cost to benefit for the malaria vaccine. 
Comparative Analysis 
 Looking at the costs and benefits of LLINs and the RTS,S vaccine should provide some 
insight into whether the hundreds of millions of dollars spent in its development have been 
worthwhile. Since the exact model of LLIN that is most commonly provided is not known nor 
has the final price of RTS,S been set by the manufacturer, the low and high commercial prices 
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for known nets and vaccines will be used. It is also important to note that the vaccine price will 
reflect the need to triple-dose patients to receive immunity as per the procedure of the clinical 
trial. Thus we will assume a per-net retail cost of $38.99 or $149.99 and a single immunity cost 
for a GlaxoSmithKline vaccine of $28.50 or $386.25. The vaccine pricing is a reflection of the 
previously mentioned GlaxoSmithKline pricing schedule and the three dose treatment used in the 
clinical trial. 
 
Net Vaccine 
Cost 
Difference % 
High Price 149.99 386.25 -61.16 
Low Price 38.99 28.5 36.81 
 
On the low end the mosquito net was approximately 37% more expensive than the vaccine while 
on the high end it was 61% cheaper. Taking that into account, the question becomes whether the 
cost difference is justified by the effectiveness. Recall that the RTS,S trial reported that 75% of 
participants slept under ITNs which provide a baseline reduction in infection of 50%. 
.75*.50=.375 So assume that the trial began with a baseline success rate of 37.5%. The success 
rates reported by the trial were 47% for children and 27% in infants over the control group, 
which as commentators noted were well below the levels normally considered acceptable for 
vaccines. (Kelland & Hirschler, 2011) Taking those values into account, we can estimate the 
overall effectiveness of the vaccine as follows: .375*.47=.17625; .375*.27=.10125 Thus the 
vaccine may only have accounted for 10.1% to 17.6% of the total infection prevention in the 
trial.  
Conclusion  
Given that result, we can conclude that on the high end the vaccine’s cost is not 
warranted, as it is not providing 61% more protection than a mosquito net. If GlaxoSmithKline is 
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able to keep costs down close to the low end then the cost could be justified as the cost savings 
of the vaccine vs. the net is positive. It is still higher than the benefit that the current vaccine 
provides, indicating some amount of inefficiency, but that may be forgivable if the vaccine is 
viewed as complementary to the rest of the eradication program. However, the question will still 
remain as to whether this justifies the current expenditure to arrive at the RTS,S vaccine. Given 
GlaxoSmithKline’s outlays spent researching the drug it is hard to imagine that the price will be 
as low as flu vaccines, which would erode the benefit of the vaccine over the provision of nets. 
Those involved in malaria eradication will need to closely follow the ongoing development of 
RTS,S and other emerging vaccines to determine if the cost is justified. If the price remains high 
the vaccine will prove problematic for widespread distribution and would necessarily be viewed 
as a luxury rather than a necessity. The overall effectiveness and reliability of mosquito netting 
would necessarily take priority over the marginal benefit of the current vaccines. This issue is 
still evolving, so as more trials are conducted this analysis will become more informed and 
precise. Additional research is also necessary to determine the effect that eradication efforts are 
having on infection rates. As of this moment it does not appear that the benefit of research into 
the malaria vaccine has been worth the cost, and it would be better to focus on reducing infection 
using known means. Given the costs associated with treatment and the continued prevalence of 
malaria within Africa it may be time to shift focus back to eradication. In those countries where 
eradication worked malaria treatment is a non-factor and has freed up considerable manpower 
and funding for other health concerns, while as long as the parasite survives in Africa there will 
always be a risk that the disease could adapt to treatment methods and return to epidemic levels. 
Given the continued costs of treatment and development of new medications and vaccines it is 
worth consideration. 
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